This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Amantadine
An NMDA receptor antagonist and weak dopamine agonist originally developed as an antiviral, now used for Parkinson's disease and off-label for cognitive fatigue and TBI recovery.
Benefits
What is Amantadine?
Amantadine (marketed as Symmetrel, Gocovri, and Osmolex) is a unique pharmacological agent with a dual mechanism of action as both an NMDA glutamate receptor antagonist and a dopamine-enhancing agent. Originally developed in the 1960s as an antiviral medication for influenza A, its dopaminergic and neuroprotective properties were discovered serendipitously and have since become its primary clinical applications. Amantadine is FDA-approved for the treatment of Parkinson's disease (both as monotherapy and as adjunctive treatment for levodopa-induced dyskinesias) and for drug-induced extrapyramidal symptoms. Its NMDA receptor antagonism provides neuroprotective effects by reducing glutamate-mediated excitotoxicity, while its dopamine-enhancing properties improve motor and cognitive function in conditions characterised by dopamine deficiency.
In the cognitive enhancement context, Amantadine has gained significant attention for its off-label use in traumatic brain injury (TBI) recovery, where it has been shown to accelerate the pace of functional recovery. A landmark randomised controlled trial by Giacino et al. (2012) published in the New England Journal of Medicine demonstrated that Amantadine (100-200 mg twice daily) significantly accelerated functional recovery in patients with traumatic disorders of consciousness. Beyond TBI, clinicians have prescribed Amantadine for post-viral cognitive fatigue (including post-COVID brain fog), multiple sclerosis-related fatigue, and ADHD-like symptoms. Its combination of glutamate modulation and dopamine enhancement gives it a distinctive profile among cognitive-enhancing agents, addressing both neuroprotection and neurotransmitter deficiency simultaneously. The drug is generally well-tolerated with decades of clinical experience supporting its safety profile.
- NMDA receptor antagonism: Acts as an uncompetitive antagonist at NMDA-type glutamate receptors, blocking excessive calcium influx through the receptor channel and providing neuroprotection against glutamate-mediated excitotoxicity
- Dopamine release enhancement: Increases dopamine release from presynaptic terminals in the striatum and prefrontal cortex, improving dopaminergic signalling involved in motivation, reward, and executive function
- Dopamine reuptake inhibition: Blocks the dopamine transporter (DAT) to a modest degree, prolonging dopamine's action at post-synaptic receptors in mesolimbic and mesocortical pathways
- Sigma receptor agonism: Interacts with sigma-1 receptors, which are involved in neuroplasticity, calcium signalling, and neuroprotection, potentially contributing to its cognitive and neuroprotective effects
- Nicotinic receptor modulation: Acts as a weak antagonist at nicotinic acetylcholine receptors, which may modulate cholinergic neurotransmission and contribute to its complex pharmacological profile
- Anti-inflammatory effects: Reduces neuroinflammation by modulating microglial activation and suppressing pro-inflammatory cytokine release, supporting recovery from neurological injury
- Parkinson's disease: 100 mg twice daily, with some patients requiring up to 400 mg daily; extended-release formulations (Gocovri) are dosed at 137-274 mg once daily at bedtime
- Traumatic brain injury: 100-200 mg twice daily (200-400 mg total daily dose), as used in the Giacino et al. (2012) NEJM trial demonstrating accelerated recovery
- Cognitive fatigue: 100-200 mg daily, typically taken in the morning or split into morning and midday doses to avoid insomnia
- Starting dose: 100 mg once daily for the first week, increasing to 100 mg twice daily based on tolerability; renal dose adjustment required for patients with impaired kidney function
- Timing: Morning and early afternoon dosing preferred to minimise insomnia; last dose should generally be taken no later than 4 PM
- Common side effects: Insomnia, dizziness, nausea, dry mouth, constipation, and orthostatic hypotension are the most frequently reported adverse effects, typically mild and dose-related
- Livedo reticularis: A distinctive mottled, purplish discolouration of the skin (particularly on the legs) occurs in approximately 5-10% of patients and is reversible upon discontinuation
- CNS effects: Can cause hallucinations, confusion, agitation, and in rare cases psychotic episodes, particularly in elderly patients or those with pre-existing psychiatric conditions
- Renal clearance: Amantadine is primarily excreted unchanged by the kidneys; dose reduction is essential in patients with renal impairment to prevent accumulation and toxicity
- Discontinuation: Abrupt withdrawal should be avoided as it can precipitate neuroleptic malignant syndrome-like reactions, Parkinsonian crisis, or rebound symptoms; gradual taper over 1-2 weeks is recommended
- QT prolongation: May prolong the QT interval at higher doses or in combination with other QT-prolonging medications; ECG monitoring may be warranted in at-risk patients
Natural Sources & Forms
- Giacino et al. (2012): "Placebo-controlled trial of amantadine for severe traumatic brain injury" in the New England Journal of Medicine, the landmark trial demonstrating accelerated functional recovery
- Crosby et al. (2012): "Amantadine for traumatic brain injury" in the Annals of Pharmacotherapy, reviewing the evidence for cognitive and functional benefits
- Hubsher et al. (2012): "Amantadine: the journey from fighting flu to treating Parkinson disease" in Neurology, reviewing the drug's pharmacological history and mechanisms
- FDA prescribing information: Complete prescribing information for Symmetrel (amantadine hydrochloride) including pharmacokinetics, clinical data, and comprehensive safety warnings
- Sawyer et al. (2008): "Use of amantadine for cognitive impairment" review in the American Journal of Physical Medicine and Rehabilitation covering off-label cognitive applications
Frequently Asked Questions
An NMDA receptor antagonist and weak dopamine agonist originally developed as an antiviral, now used for Parkinson's disease and off-label for cognitive fatigue and TBI recovery.
The key benefits of Amantadine include: Cognitive Enhancement, Energy, Focus, Longevity, Memory, Mood, Motivation.
NMDA receptor antagonism: Acts as an uncompetitive antagonist at NMDA-type glutamate receptors, blocking excessive calcium influx through the receptor channel and providing neuroprotection against glutamate-mediated excitotoxicity Dopamine release enhancement: Increases dopamine release from presynaptic terminals in the striatum and prefrontal cortex, improving dopaminergic signalling involved in motivation, reward, and executive function Dopamine reuptake inhibition: Blocks the dopamine transporter (DAT) to a modest degree, prolonging dopamine's action at post-synaptic receptors in mesolimbic and mesocortical pathways Sigma receptor agonism: Interacts with sigma-1 receptors, which are involved in neuroplasticity, calcium signalling, and neuroprotection, potentially contributing to its cognitive and neuroprotective effects Nicotinic receptor modulation: Acts as a weak antagonist at nicotinic acetylcholine receptors, which may modulate cholinergic neurotransmission and contribute to its complex pharmacological profile Anti-inflammatory effects: Reduces neuroinflammation by modulating microglial activation and suppressing pro-inflammatory cytokine release, supporting recovery from neurological injury
Parkinson's disease: 100 mg twice daily, with some patients requiring up to 400 mg daily; extended-release formulations (Gocovri) are dosed at 137-274 mg once daily at bedtime Traumatic brain injury: 100-200 mg twice daily (200-400 mg total daily dose), as used in the Giacino et al. (2012) NEJM trial demonstrating accelerated recovery Cognitive fatigue: 100-200 mg daily, typically taken in the morning or split into morning and midday doses to avoid insomnia Starting dose: 100 mg once daily for the first week, increasing to 100 mg twice daily based on tolerability; renal dose adjustment required for patients with impaired kidney function Timing: Morning and early afternoon dosing preferred to minimise insomnia; last dose should generally be taken no later than 4 PM
Common side effects: Insomnia, dizziness, nausea, dry mouth, constipation, and orthostatic hypotension are the most frequently reported adverse effects, typically mild and dose-related Livedo reticularis: A distinctive mottled, purplish discolouration of the skin (particularly on the legs) occurs in approximately 5-10% of patients and is reversible upon discontinuation CNS effects: Can cause hallucinations, confusion, agitation, and in rare cases psychotic episodes, particularly in elderly patients or those with pre-existing psychiatric conditions Renal clearance: Amantadine is primarily excreted unchanged by the kidneys; dose reduction is essential in patients with renal impairment to prevent accumulation and toxicity Discontinuation: Abrupt withdrawal should be avoided as it can precipitate neuroleptic malignant syndrome-like reactions, Parkinsonian crisis, or rebound symptoms; gradual taper over 1-2 weeks is recommended QT prolongation: May prolong the QT interval at higher doses or in combination with other QT-prolonging medications; ECG monitoring may be warranted in at-risk patients
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!